# A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

> **NCT00574704** · PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG** · enrollment: 40 (actual)

## Conditions studied

- Perennial Allergic Rhinoconjunctivitis
- House Dust Mite Allergy

## Interventions

- **DRUG:** CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- **DRUG:** House dust mite allergen extract in combination with CYT003-QbG10-placebo
- **DRUG:** CYT003-AllQbG10 in combination with house dust mite allergen extract placebo
- **DRUG:** CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo

## Key facts

- **NCT ID:** NCT00574704
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574704, "A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00574704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*